Vemurafenib Not Yet Recruiting Phase 2 Trials for BRAF V600E Mutation Present / Papillary Craniopharyngioma Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03224767Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma